Business● LowSep 23 · Sep 23, 2026, 10:18 AM
BoomRay and Novartis Pharma sign $900m deal for radioligand therapy
GlobeAlert Desk · curated from Yahoo Finance · global
BoomRay and Novartis Pharma have signed a $900 million deal concerning radioligand therapy. This represents a significant business transaction in the pharmaceutical industry.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business4m agoKornit Digital Non-GAAP EPS of $0.11 beats by $0.06, revenue of $58.34M beats by $0.86MSeeking Alpha TechBusiness5m agoEgyptian economy growth slows to 4.9% in Q1Asharq Al-Awsat [ar] · Saudi ArabiaBusiness6m agoKandi Technologies GAAP EPS of $0.57, revenue of $82.1MSeeking Alpha TechBusiness6m agoHow the car sales business changed in Argentina: how much profit margin fell and what dealerships are looking forInfobae · Argentina